Changes in transcriptomic landscape in human end-stage heart failure with distinct etiology

Zhu, Miaomiao; Zhang, Chao; Zhang, Zhe; Liao, Xudong; Ren, Dazhong; Li, Rui; Liu, Shiliang; He, Ximiao; Dong, Nianguo

doi:10.1016/j.isci.2022.103935

Cited by 7 publications

(11 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data on circRNA-miRNA-mRNA networks in IHF are still limited, primarily restricted to end-stage IHF patients [40][41][42]. In this study, the aim was to establish a large-scale regulatory network based on the ceRNA theory involving multiple types of RNAs, including circRNAs, miRNAs, and mRNAs, identified in non-end-stage IHFs patients.…”

Section: Discussionmentioning

confidence: 99%

“…On account of these data, a deep knowledge of the functional interactions among the different families of coding and non-coding RNAs may help shed light on the phenotypic consequences of the transcriptomic dysregulations in the HF process. Indeed, the very few data on circRNA-miRNA-mRNA networks in IHF [40][41][42] are limited to end-stage patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

circRNA-miRNA-mRNA Deregulated Network in Ischemic Heart Failure Patients

Madè,

Bibi,

Garcia-Manteiga

et al. 2023

Cells

View full text Add to dashboard Cite

Noncoding RNAs (ncRNAs), which include circular RNAs (circRNAs) and microRNAs (miRNAs), regulate the development of cardiovascular diseases (CVD). Notably, circRNAs can interact with miRNAs, influencing their specific mRNA targets’ levels and shaping a competing endogenous RNAs (ceRNA) network. However, these interactions and their respective functions remain largely unexplored in ischemic heart failure (IHF). This study is aimed at identifying circRNA-centered ceRNA networks in non-end-stage IHF. Approximately 662 circRNA-miRNA-mRNA interactions were identified in the heart by combining state-of-the-art bioinformatics tools with experimental data. Importantly, KEGG terms of the enriched mRNA indicated CVD-related signaling pathways. A specific network centered on circBPTF was validated experimentally. The levels of let-7a-5p, miR-18a-3p, miR-146b-5p, and miR-196b-5p were enriched in circBPTF pull-down experiments, and circBPTF silencing inhibited the expression of HDAC9 and LRRC17, which are targets of miR-196b-5p. Furthermore, as suggested by the enriched pathway terms of the circBPTF ceRNA network, circBPTF inhibition elicited endothelial cell cycle arrest. circBPTF expression increased in endothelial cells exposed to hypoxia, and its upregulation was confirmed in cardiac samples of 36 end-stage IHF patients compared to healthy controls. In conclusion, circRNAs act as miRNA sponges, regulating the functions of multiple mRNA targets, thus providing a novel vision of HF pathogenesis and laying the theoretical foundation for further experimental studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

circRNA-miRNA-mRNA Deregulated Network in Ischemic Heart Failure Patients

Madè,

Bibi,

Garcia-Manteiga

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…1). В общей сложности для трех подгрупп СН, выделенных на основании этиологического фактора, общими в суммарной выборке пациентов с СН были 165 из 2402 ДЭГ circРНК, и 15 из 120 ДЭГ микроРНК [4]. Различия по уровню и динамике зарегистрированы для ряда циркулирующих в крови микроР-НК между пациентами с острой СН (ОСН) и хронической СН (ХСН) [27]: по сравнению с ХСН при острой ОСН на начальном этапе наблюдения (при госпитализации) уровни циркулирующей miR-22 были в 1,9 раза выше, miR-92а выше в 1,25 раза, а уровни miR-499 в 5 раз ниже, а затем наблюдалось ступенчатое повышение (через 48, 120 ч) уровней всех трех исследованных микроРНК при ОСН, но не при ХСН.…”

Section: сибирский журнал клинической и экспериментальной медициныunclassified

“…Многие генетические варианты, ассоциированные с риском развития СН, могут быть вовлечены в эпигенетическую регуляцию [3]. Этот факт, а также данные транскриптомных исследований (изменение экспрессионных профилей по мере развития патологического процесса и их нормализация после отмены неблагоприятного воздействия) [4,5] указывают на потенциальную значимость эпигенетических факторов в прогрессии СН.…”

Section: Introductionunclassified

Epigenetic factors of heart failure (review)

Kucher,

Nazarenko

2024

SJCEM

View full text Add to dashboard Cite

Heart failure (HF) is a widespread syndrome that leads to a significant decrease in the quality of life of patients. Epigenetics is one of the most promising areas of HF research, which allows us to consider the pathogenesis of this syndrome at a new molecular level. This review summarizes the studies of epigenetic processes (histone modification, DNA methylation, changes in the expression of regulatory non-coding RNAs) that accompany HF development. Epigenetic studies of HF not only confirmed the clinical and etiological heterogeneity of this syndrome, but also expanded the range of potential diagnostic markers and opened up new drug development strategies.

show abstract

“…By comparing the plasma metabolomes between ACM patients and healthy individuals, affected metabolites and lipids further revealed several changed metabolic pathways, including lysine degradation, tryptophan metabolism, and the beta-oxidation of fatty acids ( 52 ). A recent paper compared transcriptional changes in RCM, ischemic heart disease, and valvular heart disease to control human hearts and showed that ATP metabolic processes were enriched by altered genes in RCM but not in the other two heart diseases ( 53 ). Combined, these findings highlighted the potential benefits of restoring a balanced metabolism in inherited cardiomyopathies.…”

Section: Metabolic Changes In Inherited Cardiomyopathiesmentioning

confidence: 99%

Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies

Gaar-Humphreys

Brink²,

Wekking³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Inherited cardiomyopathies caused by pathological genetic variants include multiple subtypes of heart disease. Advances in next-generation sequencing (NGS) techniques have allowed for the identification of numerous genetic variants as pathological variants. However, the disease penetrance varies among mutated genes. Some can be associated with more than one disease subtype, leading to a complex genotype-phenotype relationship in inherited cardiomyopathies. Previous studies have demonstrated disrupted metabolism in inherited cardiomyopathies and the importance of metabolic adaptations in disease onset and progression. In addition, genotype- and phenotype-specific metabolic alterations, especially in lipid metabolism, have been revealed. In this mini-review, we describe the metabolic changes that are associated with dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), which account for the largest proportion of inherited cardiomyopathies. We also summarize the affected expression of genes involved in fatty acid oxidation (FAO) in DCM and HCM, highlighting the potential of PPARA-targeting drugs as FAO modulators in treating patients with inherited cardiomyopathies.

show abstract

Changes in transcriptomic landscape in human end-stage heart failure with distinct etiology

Cited by 7 publications

References 59 publications

circRNA-miRNA-mRNA Deregulated Network in Ischemic Heart Failure Patients

circRNA-miRNA-mRNA Deregulated Network in Ischemic Heart Failure Patients

Epigenetic factors of heart failure (review)

Targeting lipid metabolism as a new therapeutic strategy for inherited cardiomyopathies

Contact Info

Product

Resources

About